These observations, and the reported results that ZMIZ1 cannot co-activate ER in the original AR-ZMIZ1 interaction studies, suggest that the ER−ZMIZ1 interaction in breast cancer may be via a different mechanism to that in the prostate. Here, AR is linked to breast carcinoma.